Lightlake Therapeutics is Developing a New Treatment for Bulimia.
19 Mai 2011 - 8:33PM
Business Wire
Lightlake Therapeutics Inc. (OTC.BB.-LLTP), the specialist
biopharma company, is extending the range of its research into
effective treatments for eating disorders to bulimia and
amphetamine, cocaine and opioid painkiller dependencies, for which
it holds existing US and European patents.
The company will shortly be commencing trials on its bulimia
treatment and is currently carrying out a Phase II trial for its
proprietary treatment for obese and overweight patients with Binge
Eating Disorder.
Lightlake has developed a unique opioid antagonist nasal spray,
and is applying its technology and expertise to develop other
pharmacy based health delivery programmes
Dr. Michael Sinclair, the Chairman of Lightlake Therapeutics
stated:-
“Whilst Lightlake Therapeutics’ primary focus is to investigate
the use of our opioid antagonist nasal spray for obese and
overweight patients with Binge Eating Disorder, our research
suggests our proprietary technology can be extended to treat other
conditions including drug dependency, overdose, and Bulimia
Nervosa.
Opioid antagonists are very safe compounds and have been used
for over 30 years with proven efficacy for intra-nasal delivery
with minimal side effects. The treatment programmes we are
developing mean that the nasal spray is likely to be used by
patients only when they are about to undertake behaviour they wish
to extinguish.
Dr. David Sinclair, Lightlake’s Chief Scientific Officer, is a
pioneer and one of the world’s leading experts in the field of
opioid antagonists. His acclaimed Sinclair Method for the treatment
of alcoholism has been the subject of over 80 multi-centre clinical
trials with exceptional results.
The physiological mechanism for treating eating disorders and
drug dependency is identical and we confidently expect the results
of the Phase II Binge Eating Disorder trial to be as successful as
David Sinclair’s results in treating alcoholism.
The growth in importance in Pharmacy based health care delivery
programmes is notable throughout the developed world. We have
reached an agreement with Celesio, Europe’s leading pharmacy
distribution network, with 65,000 associate outlets in Europe, to
develop a pharmacy based Binge Eating Disorder treatment programme
using Lightlake’s proprietary product. We aim to extend this
community based arrangement to other emerging markets.
With US and European Government predictions that over 40% of
their citizens will be clinically obese by 2020, the market for
Lightlake’s products worldwide is considerable. Conservative
estimates are that 30% of obese and overweight individuals exhibit
binge eating behaviour. Lightlake’s estimate of the market for its
product in the US alone is 20million individuals. We anticipate
similar sized markets in Central and South America; Europe; India
and South East Asia.
We aim to deliver treatments that cost consumers less than US
$12 per week which is comparable to other products on the
market.”
About Lightlake Therapeutics, Inc.
Lightlake Therapeutics is a Biopharmaceutical Company aiming to
build a solid platform of pharmacological treatments based on its
expertise using opioid antagonists. The company through its labs in
Helsinki is currently in phase II trials in the use of an opioid
antagonist nasal spray to address binge-eating obesity. Phase II
trials are expected to be completed early in 2012.
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes,” estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward-looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
presentation to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
www.lightlaketherapeutics.com
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024